Publications by authors named "C Chazallon"
Background: Due to the low number of individuals with HIV-2, no randomised trials of HIV-2 treatment have ever been done. We hypothesised that a non-comparative study describing the outcomes of several antiretroviral therapy (ART) regimens in parallel groups would improve understanding of how differences between HIV-1 and HIV-2 might lead to different therapeutic approaches.
Methods: This pilot, phase 2, non-comparative, open-label, randomised controlled trial was done in Burkina Faso, Côte d'Ivoire, Senegal, and Togo.
Access to Hepatis C treatment in Sub-Saharan Africa is a clinical, public health and ethical concern. The multi-country open-label trial TAC ANRS 12311 allowed assessing the feasibility, safety, efficacy of a specific care model of HCV treatment and retreatment in patients with hepatitis C in Sub Saharan Africa. Between November 2015 and March 2017, with follow-up until mid 2019, treatment-naïve patients with HCV without decompensated cirrhosis or liver cancer were recruited to receive 12 week-treatment with either sofosbuvir + ribavirin (HCV genotype 2) or sofosbuvir + ledipasvir (genotype 1 or 4) and retreatment with sofosbuvir + velpatasvir + voxilaprevir in case of virological failure.
View Article and Find Full Text PDFArticle Synopsis
- People with HIV (PWH) treated for tuberculosis (TB) may develop a condition called TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) after starting antiretroviral therapy (ART), which includes integrase inhibitors like raltegravir and non-nucleoside reverse transcriptase inhibitors like efavirenz.
- A study analyzed data from the Reflate TB 2 trial, which compared the occurrence of TB-IRIS in PWH receiving either raltegravir or efavirenz-based ART while undergoing standard TB treatment.
- The results showed that the incidence of TB-IRIS was similar in both ART groups, with 48 participants developing TB-IRIS, and identified risk factors such as low CD4
Article Synopsis
- A study was conducted to compare the effectiveness of antiretroviral therapy (ART) for people with HIV who were also being treated for tuberculosis across four countries involved in two clinical trials.
- The analysis included 550 participants from Brazil, Côte d'Ivoire, Mozambique, and Vietnam, finding that 65.8% achieved virologic success, with higher rates in Brazil (75.0%) compared to Côte d'Ivoire (58.2%).
- Results indicated that the initial level of HIV-1 RNA was the main factor influencing treatment success, rather than the country of treatment.
Article Synopsis
- In the Reflate TB2 trial, researchers studied factors linked to virologic success and adherence in people with HIV and tuberculosis receiving raltegravir or efavirenz treatment.
- Out of 444 participants, 65% achieved virologic success (HIV-1 RNA <50 copies/mL) and maintained adherence (≥95% pill count) over 48 weeks, with several factors influencing these outcomes.
- Key findings indicated that female sex, lower baseline HIV-1 RNA levels, and optimal adherence were associated with virologic success, while a higher antiretroviral pill burden negatively impacted adherence.